When passing
different versions of Medicare legislation (H.R. 1 and S. 1),
providing a universal drug entitlement, the House and Senate each
deliberately ignored the Joint Economic Committee's warning: The entitlement will
massively disrupt, one way or another, existing private drug
coverage for millions of seniors, particularly the drug coverage
provided by employer plans.
What the
Drug Entitlement Will Mean for Seniors
According to the
Congressional Budget Office (CBO), if either the House or the
Senate bill were to become law, at least one-third of seniors who
receive drug coverage through their former employer would lose that
benefit.
Deep
Losses. Seniors who are dumped out of their current retiree
benefits would lose both generally superior prescription drug
coverage and thousands of dollars in deferred and future
compensation. Throughout their working lives, seniors with
employer-provided retiree drug coverage worked with the
understanding that that coverage would be there for the rest of
their lives. Some employers provided this benefit of their own free
will, and others provided it through contractual obligation, such
as union contracts like the United Auto Workers.
Retirees also
forfeited pay during their working lives for a benefit they count
on for the rest of their lives, the value of which could be as high
as $110,000 throughout their retirement depending upon the quality
of coverage.
And that would be
replaced with worse coverage. According to Ken Thorpe of Emory
University, "The actuarial value of the proposed Medicare drug
benefit is substantially less generous than retiree health
plans."
His estimates place the number of seniors dropped from their
current coverage at 4.1 million, broadly in line with CBO
estimates.
Disputes Over
Employer Responses. Not everyone agrees with the CBO and Thorpe
estimates. For example, the Employee Benefit Research Institute
(EBRI) estimate is much lower: from 2 percent to 9 percent.
However, an
important caveat in the footnotes of the EBRI study shows that what
they are saying is not necessarily different from what is being
said by other analysts who are critical of the House and Senate
bills. Footnote 5 of the EBRI report says, "We believe most
employers will choose to 'wrap-around' Medicare for current
retirees, as they generally do today."
In the context of
the Medicare legislation, this is a crucial point.
Under a
wrap-around policy an employer would cover the initial deductible
and cost-sharing expenses up to a point for its retirees. However,
this would have a perverse effect because neither the House nor
Senate bills count monies paid by a former employer's plan as part
of the beneficiary's cost-sharing in calculating when the
beneficiary reaches the catastrophic coverage level.
Thus, not only
would employer-provided wrap-around coverage not fill in the
coverage gaps in the new Part D Medicare benefit, it would
instead bunch all of the cost-sharing together into one,
even larger, coverage gap, which the beneficiary would have to pay
out-of-pocket before reaching the catastrophic coverage level.
Under the House
bill, those retirees would have to cover the next $3,500 on their
own, while the Senate bill would require them to pay the $3,700.
Once those out-of-pocket expenses were met, coverage would resume.
The House bill would cover 100 percent of prescription costs over
that limit, while the Senate bill would cover 90 percent.
There is little
doubt that seniors losing their private employer-based coverage, or
having it scaled back to wrap-around coverage will end up paying
more out of pocket for the new government drug benefit. Seniors who
lose their employer-provided coverage would see their out-of-pocket
costs increase by up to 50 percent under the Senate bill. They would also fare
poorly under the House bill.
What the Drug
Entitlement Will Mean for Corporations
While seniors
stand to lose coverage they know, trust, and have been promised,
corporations would reduce their long-term liabilities for retiree
drug coverage under both the House and Senate Medicare bills. One
example of an industry that could save millions if Medicare covered
prescription drugs and that has been lobbying for a universal drug
entitlement is the auto industry.
The auto industry
has a very high ratio of retirees to workers: roughly 475,000
retirees to only about 300,000 workers, with the ratio at General
Motors being about 2 to 1.
According to a recent report in The Economist, "This burden,
plus the fierce price-and-incentives competition in the industry,
has savaged the finances of the Big Three."
Given the
potential savings to automakers, it is no wonder they have been
"lobbying for years" for a universal drug entitlement in Medicare,
financed by the taxpayers, and not one targeted only toward those
seniors who need it.
Gary Lapidus, an analyst at Goldman Sachs, estimated that General
Motors could save as much as $150 million annually and that the
Ford Motor Company could save $50 million annually.
Edward J. Kaleta,
chairman of the Employers' Coalition on Medicare, a group lobbying
on the Medicare legislation on behalf of large corporations, has
said that "Congress should not discriminate against our retirees
because they have employer-provided coverage. Our retirees should
be treated the same as other Medicare beneficiaries."
With literally
billions of dollars at stake for corporations over the next 10
years, if the taxpayer ends up funding a new universal entitlement,
however inferior to what current retirees receive or were promised
that entitlement may be, it would be nearly impossible for publicly
owned companies not to reduce to wrap-around coverage.
A New Plea for
Corporate Welfare?
Some Members of
Congress are now proposing new government subsidies or another set
of special tax breaks as a way to prevent employers from dropping
coverage they once promised to seniors. Under such a scenario,
according to a recent report in The New York Times, "The tax
credits would be available to employers who maintain drug coverage
or supplement what Medicare provides." Companies that provide
wrap-around coverage would receive a tax credit while "the employer shifts the majority of the price
and volume risk for drug coverage onto Medicare and its own
retirees."
The National Association of Manufacturers
(NAM), the largest industrial trade association in the country with
14,000 members, supports the idea of a universal drug
entitlement.
Most corporations and trade associations avoid making any direct
pledge not to drop or reduce current retiree coverage. Congress
itself, on the other hand, has already taken the first steps to
enact a law to protect its own retirees (including retired Members
of Congress) from seeing their benefits eliminated or reduced to
the level they have enacted for all other retirees.
The creation of a universal drug entitlement,
displacing private coverage, follows a familiar pattern of bad
policymaking. Congress first creates a program, say a new
entitlement, with new fiscal obligations for the taxpayers.
Congress then discovers that the creation of this new entitlement
begets a series of unintended and very undesirable consequences.
Then, to cope with the unintended consequences of the entitlement,
Congress again hits the taxpayers with the cost of a quick fix for
the problem that it (often unnecessarily) created in the first
place.
Target Taxpayer Dollars to Those
Who Need It
Senior citizens
who currently receive prescription drug coverage through their
former employer run serious risk of losing that coverage or seeing
it significantly reduced by a universal drug entitlement added to
Medicare. At the same time, corporations that provide retirees with
prescription drug coverage stand to gain tens of millions of
dollars in savings by either dropping retiree coverage altogether
or scaling it back to provide wrap-around coverage in Medicare.
It is a mistake to saddle America's
middle-class taxpayers with an unnecessary, universal drug
entitlement of unknown cost. It is even worse to compound
that fiscal mistake by asking those very same taxpayers to dig into
their pockets and subsidize corporations so that the corporations
will not dump their retirees into a congressionally mandated
entitlement that they lobbied to create in the first
place.
A better idea is simply to solve a real
problem. Instead of creating a universal entitlement, Congress
could address the real needs of real seniors who don't have drug
coverage or access to drug coverage, and target taxpayer dollars to
those who need the most help. That would be a rational,
responsible, and fiscally sane course of action. It's not too
late.
Joint Economic Committee, U.S. Congress,
"Medicare Beneficiaries' Link to Drug Coverage," April 10,
2003.
Congressional Budget Office, "H.R. 1: Medicare
Prescription Drug and Modernization Act of 2003 and S. 1:
Prescription Drug and Medicare Improvement Act of 2003," CBO Cost
Estimate, July 22, 2003.
Lanhee J. Chen, "What
Seniors Will Lose with a Universal Medicare Drug Entitlement,"
Heritage Foundation Backgrounder No. 1680, August 26,
2003.
Ken Thorpe, "Potential
Implications of the Medicare Prescription Drug Benefit on Retiree
Health Care Benefits," Emory University, September 13, 2003.
Ibid.
Dallas L. Salisbury and
Paul Fronstin, "How Many Medicare Beneficiaries Will Lose
Employment-Based Retiree Health Benefits if Medicare Covers
Outpatient Prescription Drugs?" Employee Benefit Research
Institute, EBRI Special Analysis, July 18, 2003.
For a more detailed
discussion, see Edmund F. Haislmaier, "How Congress's Medicare Drug
Provision Would Reduce Seniors' Existing Private Coverage,"
Heritage Foundation Backgrounder No. 1668, July 17,
2003.
Lanhee J. Chen, "How the
Senate Medicare Drug Bill Would Raise Senior Citizens'
Out-of-Pocket Drug Costs," Heritage Foundation Web Memo No.
312, July 15, 2003.
"Still Power in the
Union?" The Economist, August 30, 2003, p. 45.
Ibid.
Sarah A. Webster,
"Medicare Drug Plan May Save Carmakers Millions; Retiree Health
Bills in Congress Likely to Affect UAW Talks," Detroit Free
Press, July 8, 2003.
Ibid.
Robert Pear, "Retirees
Alarmed at Threat of Cuts in Drug Benefits," The New York
Times, September 16, 2003.
Ibid.
Haislmaier, "How
Congress's Medicare Drug Provision Would Reduce Seniors' Existing
Private Coverage."